Bevacizumab

證據等級: L5

預測適應症: 10 個

Bevacizumab: From Anti-VEGF Antineoplastic Therapy to Epiglottis Neoplasm

One-Sentence Summary

Bevacizumab (Avastin) is a humanized anti-VEGF-A monoclonal antibody with established global approvals across multiple solid tumours, including colorectal cancer, non-small cell lung cancer, glioblastoma, and ovarian cancer, though it is not currently registered in Singapore. The TxGNN model predicts it may be effective for Epiglottis Neoplasm, with a high prediction score of 99.90%. However, no clinical trials and no supporting publications currently exist for this specific indication, placing this candidate at the lowest evidence level (L5) — model prediction only.

Quick Overview

Item	Content
Original Indication	Not registered in Singapore (globally: colorectal cancer, NSCLC, glioblastoma, ovarian cancer, renal cell carcinoma)
Predicted New Indication	Epiglottis Neoplasm
TxGNN Prediction Score	99.90%
Evidence Level	L5
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds and neutralizes VEGF-A (Vascular Endothelial Growth Factor A), thereby inhibiting tumour neovascularisation. By blocking the formation of new blood vessels, Bevacizumab deprives tumours of the oxygen and nutrient supply required for growth and metastasis. This anti-angiogenic mechanism is in principle tumour-agnostic and has been clinically validated across multiple histological cancer types.

Epiglottis neoplasms are tumours arising from the supraglottic larynx — a head and neck region where VEGF-mediated angiogenesis has been implicated in tumour progression and treatment resistance in adjacent anatomical sites. The TxGNN knowledge graph likely inferred this association through shared disease nodes with other head and neck cancers for which anti-VEGF strategies have shown preclinical or clinical activity. Mechanistically, Bevacizumab's ability to suppress supraglottic tumour angiogenesis provides a plausible biological rationale, even in the absence of direct clinical evidence.

However, it must be emphasised that the current standard of care for epiglottis neoplasms is surgery and/or radiochemotherapy, and no preclinical models specifically exploring anti-angiogenic therapy in this entity have been established. The prediction at this stage rests entirely on knowledge graph inference, and the risk-benefit profile for systemic anti-VEGF therapy in this uncommon indication has not been characterised.

Clinical Trial Evidence

Currently no related clinical trials registered for this indication.

Literature Evidence

Currently no related literature available for this indication.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (Anti-VEGF-A humanized monoclonal antibody; not conventional cytotoxic)
Myelosuppression Risk	Low (Bevacizumab does not directly suppress bone marrow; haematological toxicity is primarily driven by any co-administered chemotherapy)
Emetogenicity Classification	Low
Monitoring Items	Blood pressure (hypertension is common), urinalysis for proteinuria, wound healing assessment, signs of gastrointestinal perforation, thromboembolic events, and haemorrhage; CBC if combined with cytotoxic agents
Handling Protection	Follow institutional biologic/monoclonal antibody handling protocols; standard precautions apply (not classified as a conventional hazardous cytotoxic agent for handling purposes)

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN model assigns a high knowledge-graph prediction score (99.90%), epiglottis neoplasm is an Evidence Level L5 candidate — supported solely by computational inference with no clinical trials, no published literature, and no preclinical data. The absence of even mechanistic or preclinical evidence, combined with well-established surgical and radiochemotherapy standards for this indication, does not support advancing to clinical investigation at this time.

To proceed, the following is needed:

Preclinical studies (in vitro/in vivo tumour models) establishing VEGF dependency specifically in epiglottis neoplasm
Systematic review of VEGF/angiogenesis expression data in supraglottic tumour tissue
Retrieval and parsing of the Singapore (HSA) / global package insert for complete warnings and contraindications data
Mechanism of action (MOA) data from DrugBank to support mechanistic rationale analysis
Assessment of unmet medical need and eligible patient population size to determine feasibility of future study design
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.